| | 
Part, Chapter, Paragraph
1 II, 5. 2. 4| hypertension prevalence ( 160 o 95 mmHg; 140 o 90 mmHg; 160
2 II, 5. 2. 7| 2000. Am J Public Health 95 (1): 103-108.~WHO Expert
3 II, 5. 4. 2| 12 months. The median is 95% for Germany. This clinical
4 II, 5. 5. 1| 5.1.2. Odds ratio (with 95% confidence interval) for
5 II, 5. 5. 1| 5.1.3. Odds ratio (with 95% confidence interval) for
6 II, 5. 5. 1| 5.1.4. Odds ratio (with 95% confidence interval) for
7 II, 5. 5. 2| 80-84, 85-89, 90-94 and 95-99).~ ~The study included
8 II, 5. 5. 3| Eating Disorder 41:1 92-95.~Hoek H W, van Hoeken D, (
9 II, 5. 5. 3| seizure onset was 0.94 (95% CI 0.91-0.97), 0.88 (95%
10 II, 5. 5. 3| 95% CI 0.91-0.97), 0.88 (95% CI 0.84-0.92), and 0.75 (
11 II, 5. 5. 3| CI 0.84-0.92), and 0.75 (95% CI 0.74-0.86), respectively.~
12 II, 5. 5. 3| remission had a 9.3 RR of death (95% CI 3.8-22.7) compared with
13 II, 5. 5. 3| be even higher (SMR 87.5; 95% CI 35-180) in patients
14 II, 5. 5. 3| SMR (all causes) was 4.9 (95% CI 2.7-8.3) vs. 7.9 (95%
15 II, 5. 5. 3| 95% CI 2.7-8.3) vs. 7.9 (95% CI 2.6-18.4) in non-surgical
16 II, 5. 6. 3| chronic musculoskeletal pain (95% Cl) among all respondents (
17 II, 5. 6. 6| elderly people. BMJ 327:89-95~Woolf AD, Pfleger B (2005):
18 II, 5. 7. 7| Intern Med 2004 Jul 20;141(2):95-101.~Jager KJ, van Dijk
19 II, 5. 8. 3| of depression (OR 3.52, 95%CI 2.04 to 6.07) compared
20 II, 5. 9. FB| in relative risk (RR 1.5, 95% CI 1.2 to 1.8). The combined
21 II, 5. 9. FB| had a pooled RR of 1.2 (95% CI 1.1 to 1.3) and concluded
22 II, 5. 9. 2| asthma 507.8~Wood asthma 95.8~Miner’s asthma 500)~·
23 II, 5. 9. 3| incident rate ratio = 2.63 and 95% CI = 2.20-3.12 for 1974-
24 II, 5. 9. 4| part in the ECRHS (1990-95)( European Community Respiratory
25 II, 5. 9. 4| asthma (relative risk=1.6, 95% CI 1.1-2.3, P=0.017). Risks
26 II, 5. 9. 4| chemical spills (RR=3.3, 95% CI 1.0-11.1, P=0.051).
27 II, 5. 9. 4| rhino-conjunctivitis symptoms was 0.50 (95% confidence interval (CI)
28 II, 5. 9. 4| allergic sensitization (95% CI 0.42-0.67) for farm
29 II, 5. 9. 4| odds ratio, POR = 0.39; 95% CI: 0.23-0.66) and current
30 II, 5. 9. 4| current wheeze (POR = 0.72; 95% CI: 0.47-1.10) were found
31 II, 5. 10. 3| intolerance prevalence rates and 95% Confidence Intervals per
32 II, 5. 15. 3| patients and 1,500 RD affect 95% of the patients. The estimated
33 II, 6. 3. 5| threshold, but with over 95% measles vaccine coverage;
34 II, 6. 3. 5| incidence rates (77.24 and 28.95 per 100 000, respectively).
35 II, 6. 3. 6| followed by the UK (87.95 per 100 000). Campylobacteriosis
36 II, 7. 7 | Council (2001): Directive 2001/95/EC of the European Parliament
37 II, 9. 1. 1| deaths. Obstet Gynecol 2000;95(2):215-21.~ ~Kahn B, Lumey
38 II, 9. 1. 2| year prevalence figures on 95 subgroups of congenital
39 II, 9. 3. 2| deaths. Obstet Gynecol 2000;95(2):215-21.~ ~Jackson RA,
40 III, 10. 2. 1| Community, articles 152 and 95 EC provide the legal base
41 III, 10. 3. 2| National Cancer Institute 95:1238–40~ ~Environmental
42 III, 10. 4. 2| achieve no later than 2010 a 95% reduction in emissions
43 III, 10. 4. 2| origin, and Council Directive 95/69/EC of 22 December 1995
44 III, 10. 4. 2| Commission (1995): Decision No. 95/69/EC of 22 December 1995
45 IV, 11. 1. 5| 489-bed hospital and a 3.95% decline in the hospital’
46 IV, 11. 6. 5| evidence for 1987-88 and 1994-95 in British Columbia." Age
47 IV, 11. 6. 5| Security Policy 3(2): 80-95.~ ~Sorenson C, Kanavos P
48 IV, 12. 1 | sanitary services)~ ~Art. 95 (3), (6) and (8) concerning
49 IV, 12. 1 | Data~and Privacy~Directive 95/ 46/EC on data protection~
50 IV, 12. 2 | Community, articles 152 and 95 EC provide the legal base
51 IV, 12. 10 | the Council Directive 2002/95 “on the restriction of the
52 IV, 12. 10 | health~ Intermediate~Law 95/04/2006 for health system
53 IV, 12. 10 | Hypertension~ Intermediate~ Law 95/2006 on Health Reform~During
54 IV, 13. 7. 5| Data Protection (Directive 95/46/EC) is of major importance
55 IV, 13. 7. 5| have transposed Directive 95/46/EC . Nevertheless, the
56 IV, 13. 9 | Commission (1995): Directive 95/46/EC of the European Parliament
|
|
| |
